|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1984-8-24
|
|
pubmed:abstractText |
We have characterized the epitope of the rat monoclonal antibody YL 1/2 in detail using synthetic peptides and several alpha-tubulin derivatives. The epitope seems to be provided by the linear sequence spanning the carboxy-terminal residues of tyrosinated alpha-tubulin. By competitive ELISA, dipeptides covering the carboxyl end could be antigenically recognized. Three sites were deduced at the dipeptide level: a negatively charged side chain in the penultimate position followed by an aromatic residue which must carry the free carboxylate group. Experiments with longer peptides point to a further negative charge provided by a carboxylate group on the third residue from the end. Thus the tripeptide Glu-Glu-Tyr was only 5-fold less active than the octapeptide spanning the carboxy-terminal alpha-tubulin sequence. The octapeptide itself showed only a 40-fold lower activity than tyrosinated alpha-tubulin. In line with the emerging epitope requirements of YL 1/2, the Escherichia coli rec A protein, the catalytic subunit of the cyclic AMP-dependent muscle protein kinase as well as performic acid-oxidized actin were recognized by YL 1/2 in immunoblots. These results thus define the sequence requirements within a probably linear epitope and give rise to some general questions concerning experiments where monoclonal antibodies are microinjected into cells in order to assess the contribution of a known antigen to cellular physiology.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-1057175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-1172191,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-1191253,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-1218078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-14012745,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-264238,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-388439,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-4118873,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-4514990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-465136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-499690,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-5135623,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-53189,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-5663399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-574193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6117824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6159543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6181415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6254066,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6262777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6304456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-637870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6415068,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6546378,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6685128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6811596,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-688394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6930655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-6985485,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-7045684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-7048019,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-7310871,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-7464932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-861204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6204858-87220
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0261-4189
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1295-300
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1984
|
|
pubmed:articleTitle |
Amino acid sequence requirements in the epitope recognized by the alpha-tubulin-specific rat monoclonal antibody YL 1/2.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
